EZH2 抑制剂的结构特征和SARS
Ruosong Qin1, Baohong Ma1, Shuo Mou2
1College of Pharmacy of Liaoning University, API Engineering Technology Research Center of Liaoning Province, Small Molecular Targeted Drug R&D Engineering Research Center of Liaoning Province, Shenyang, 110036, Liaoning, People's Republic of China.
增强质同源2 (EZH2) 是许多癌症的关键驱动因素,促进瘤生长和对治疗的抵抗力. 本综述分析了新的EZH2抑制剂,重点关注它们的结构和改善癌症治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 增强体同源2 (EZH2) 是多抑制复合体2 (PRC2) 的催化子单元,对H3K27me3甲基化和基因沉默至关重要.
- 过度表达EZH2在各种癌症中很普遍,与增加的扩散,入侵,转移,治疗耐药性和不良预后相关.
研究的目的:
- 系统地审查EZH2抑制剂开发的最新进展.
- 根据结构支架对抑制剂进行分类,并分析结构-活性关系 (SARs).
- 评估临床前EZH2抑制剂用于向癌症治疗的药理学特征,优势和局限性.
主要方法:
- 对EZH2抑制剂开发的系统文献综述.
- 根据核心结构支架对抑制剂的分类.
- 分析结构-活性关系 (SARs) 和药理学数据.
主要成果:
- 基于结构支架的EZH2抑制剂类别的概述.
- 对代表性临床前化合物进行详细的SAR分析.
- 评估新兴抑制剂的药理性质,益处和缺点.
结论:
- EZH2抑制剂在治疗各种恶性瘤方面表现有前途,其中包括用于淋巴瘤的已批准药物.
- 了解SAR和药理学特征,可以指导下一代EZH2抑制剂的设计.
- 未来的EZH2抑制剂旨在提高癌症治疗中的选择性,安全性和转化潜力.
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...


